Citius Pharmaceuticals, Inc. — Director's Dealing 2021

Oct 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2021-10-11

Reporting Person: HOLUBIAK MYRON Z (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-11	Options to Purchase Common Stock	$2.04	A	650000	Acquired	2031-10-11	Common Stock (650000)	Direct
2021-10-11	Options to Purchase Common Stock	$2.04	A	15000	Acquired	2031-10-11	Common Stock (15000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1992243	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant to Purchase Common Stock	$1.15	2023-08-14	Common Stock (784314)	784314	Direct
Options to Purchase Common Stock	$8.1	2025-10-01	Common Stock (26667)	26667	Direct
Options to Purchase Common Stock	$3.45	2027-09-13	Common Stock (40000)	40000	Direct
Options to Purchase Common Stock	$1.62	2028-09-04	Common Stock (150000)	150000	Direct
Warrant to Purchase Common Stock	$1.42	2024-04-05	Common Stock (129450)	129450	Direct
Warrant to Purchase Common Stock	$0.77	2024-09-27	Common Stock (558597)	558597	Direct
Options to Purchase Common Stock	$0.67	2029-10-08	Common Stock (175000)	175000	Direct
Options to Purchase Common Stock	$1.01	2030-10-06	Common Stock (200000)	200000	Direct
Options to Purchase Common Stock	$2.00	2031-07-22	Common Stock (300000)	300000	Direct
Options to Purchase Common Stock	$2.00	2031-07-22	Common Stock (10000)	10000	Indirect

Footnotes

F1: The warrant is fully vested and exercisable immediately.

F2: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.

F3: The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015.

F4: One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest.

F5: One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.

F6: The options were granted on October 8, 2019. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

F7: The options were granted on October 6, 2020. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

F8: The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

F9: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.

F10: The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.